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Thesis Summary
Polo-Like Kinase 1 (PLK1) is a protein that has been found to be overexpressed in a
variety of cancers including prostate and colorectal cancers, and it is often an indicator of poor
patient prognosis. It has functions in initiating, maintaining, and completing mitosis, so it has an
important role in controlling the proliferation of cells. PLK1 contains a highly conserved
catalytic kinase domain and a less-conserved Polo Box Domain (PBD). Inhibiting the
phospho-ligand binding of the PBD is a potential cancer therapy because it would prevent the
cell from properly completing the cell cycle, thus inducing apoptosis. In Dr. McInnes’ lab, a
partner lab to Dr. Wyatt’s lab, a technique called Replacement with Partial Ligand Alternatives
through Computational Enrichment (REPLACE) was used to develop Fragment ligand inhibitory
peptides (FLIPs) using the recognition sequences of PLK1 PBD substrates. The FLIPs were used
as a guide to develop ABBA (2-(4-alkylbenzamido)benzoic acid), a small-molecule inhibitor.
This project involved the performance of a structure-activity relationship (SAR) analysis
on several ABBA and FLIP molecules with slight chemical alterations to determine the chemical
structures that had the highest binding affinity to PLK1 PBD. The molecules were compared
using half maximal inhibitory concentrations (IC50), which are the concentrations of inhibitor
that bind 50% of the PLK1 PBD in a sample. These values were determined through the
performance of a fluorescence polarization (FP) assay. Polo-Like Kinase 3 (PLK3) is a protein in
the mammalian PLK family that functions as a tumor suppressor, so the molecules that would
have the best potential as guides for anticancer drugs should have high specificity for PLK1 over
PLK3. In this project, the IC50 values
of 26 inhibitor molecules were determined to observe

which specific chemical alterations increased their affinity and specificity to PLK1 PBD.
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Introduction
PLK1 PBD and p53 gene
Polo-Like Kinases (PLKs) are proteins that have been found to play an important role in
regulating the progression of a cell through the cell cycle, specifically initiating, maintaining and
completing mitosis (Liu, 2016). PLK1 is one of the mammalian PLK family members, and it is
expressed in dividing cells in human tissue. Mice that have a homozygous deletion of PLK1 are
not viable, and mice with a heterozygous deletion develop tumors, so PLK1 plays an important
role in the normal proliferation of cells (Strebhardt, 2010). The other mammalian PLK family
members include PLK2, PLK3, PLK4, and PLK5. PLKs 1, 2, and 3 contain an N-terminal
Serine/Threonine catalytic kinase domain that is highly conserved in terms of amino acid
sequence and 3-D structure. This means that the sequence for the kinase domain has remained
relatively unchanged over time, and many proteins contain similar kinase domains. The PLKs
also contain a less-conserved Polo Box Domain (PBD) that has two regions: PB1 and PB2
(Strebhardt & Ullrich, 2006). The PBD is a very specific binding domain that docks substrates
and is involved with intracellular localization of the kinase. Studies have shown that
PBD-phospholigand binding is necessary for proper cell progression through mitosis. (Elia et al.,
2003). Once the PBD binds to its substrate, the kinase domain can then phosphorylate the
substrate and progress the cell through mitosis. Inhibiting the PBD from binding to its substrate
prevents this phosphorylation and can prevent the cell from properly completing mitosis.
P53 is a gene that encodes a protein referred to as a tumor-suppressor, and it functions in
regulating the cell cycle. It is known as the “guardian of the genome” because it prevents
genome mutations by inducing apoptosis, or programmed cell death, of mutated cells as they
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Figure 1: The structure of PLK1 includes the Polo-Box Domain with regions PB1 and PB2, as well as the
Serine/Threonine catalytic kinase domain.

progress through mitosis. A wild-type, or non-mutated, p53 gene represses the expression of
PLK1 as well as regulates its expression during mitosis. Thus, a mutation in the p53 gene leads
to higher levels of PLK1 expression, leading to less control over proliferating cells (McKenzie et
al., 2015). The hallmarks of cancer are biological capabilities of cells that facilitate their
transition into human tumors from benign cells. (Hanahan & Weinberg, 2011). One of the six
fundamental hallmarks of cancer is the evasion of both growth suppressors and apoptosis, and a
mutated p53 gene provides cells with a mechanism for this hallmark. PLK1 has been found to be
highly over-expressed in a variety of cancers including pancreatic and gastric carcinoma tumors,
among others. Patients with tumors containing high levels of expressed PLK1 have a worse
prognosis than those without high PLK1 expression (Abdelfatah, 2019). Inhibiting cell
proliferation and reactivating apoptosis of mutated cells are basic principles in anticancer
therapy, and PLK1 has the potential to be an anti tumor drug target because of its involvement in
progressing the cell cycle regardless of genome mutations (Elez et al., 2003).
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FLIP and ABBA molecules
This research project aimed to study a series of small molecule inhibitors (SMI) and
fragment ligand inhibitory peptides (FLIPs) with slight chemical alterations to determine which
structures had higher binding affinities to PLK1 PBD. With subsequent improvements, these
structures can guide the development of drugs that induce apoptosis of cancer cells with a
mutated p53 gene. These molecules were synthesized to target the PBD rather than the kinase
domain because over 500 different kinases exist with similar binding sites due to its high
conservation. Targeting the kinase domain would result in potentially harmful off-target effects.
Studies have also shown that one single mutation in the kinase domain causes it to be resistant to
inhibitors, which would be problematic for a drug created to inhibit the kinase domain. Even
when working with the PBD, difficulties arise when creating a PLK1 selective drug inhibitor
because PLKs 1-3 are also involved in the cell cycle, although their functions are not yet
completely understood. They are all highly related in terms of amino acid sequence and three
dimensional structure. PLK3 has been shown to act as a tumor suppressor in some manner,
meaning that it has an opposite function to PLK1 (McInnes & Wyatt, 2011). Therefore, a drug
that inhibits both PLK1 and PLK3 may cause cancer to further progress rather than inhibit cell
replication. This is why it is important to take into account the selectivity that SMIs and FLIPs
have for PLK1 over PLK3.
The efficacies of the inhibitors can be compared using values known as half maximal
inhibitory concentrations (IC50). This value represents the concentration of an inhibitor that is
necessary to bind to half of the PLK1 PBD in a sample. The smaller the IC50value for an
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inhibitor, the higher its binding affinity for PLK1. Inhibitor drugs with the most potential to be
used clinically will have low IC50values for PLK1 and significantly higher IC50values for PLK3.
The molecules used in this project were developed and synthesized in a partner lab at the
University of South Carolina College of Pharmacy, Dr. McInnes’ lab. A technique called
Replacement with Partial Ligand Alternatives through Computational Enrichment (REPLACE)
was used to replace amino acid residues on the recognition sequences of two PLK1 substrate
peptides, PBIP (PLHSpTAI) and Cdc25C (LLCSpTPNGL), with small drug-like molecule
fragments. This process generated Fragment Ligand Inhibitory Peptides (FLIPs), which are used
as a guide to develop ABBA (2-(4-alkylbenzamido)benzoic acid), a small-molecule inhibitor
(Figure 2). FLIPs cannot be used as drugs because the human body naturally has peptidases that
cleave peptide bonds. FLIPs are also charged molecules, so it is difficult for them to break
through the lipid bilayer of the cell. However, they are much more active in an FP assay than
ABBA molecules (Baxter et al., 2020).

Figure 2: ABBA framework.
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Preliminary Work
Dr. Wyatt’s, Dr. McInnes’, and Dr. Elmar Nurmemmedov’s (Director of Drug Discovery
at John Wayne Cancer Institute) labs performed previous experiments that further validated
targeting of the PBD binding site for development of anti-tumor drug-like inhibitors. Using
computer molecular modeling, members of Dr. McInnes’ lab overlaid the crystal structure of the
phosphatase activating CDK1 Cdc25C peptide onto the PLK1 and PLK3 models. Observing the
amino acid residues on the phosphopeptide binding pocket through this modeling provided
information about the differences between PLK1 PBD and PLK3 PBD and served as a starting
point for REPLACE in developing the FLIP molecules. They determined that the majority of the
amino acid residues in the phosphopeptide binding region are conserved between PLK1 and
PLK3, so weaker binding of phosphopeptides to PLK3 is most likely a result of mostly
conformational differences between the two PLKs, and only slight residue differences.
Dr. Nurmemmedov’s lab examined whether the FLIPs interacted with and inhibited
PLK1 in a cellular context. Members of his lab performed a thermal shift assay, which measures
the effect of ligands (FLIPs) on the thermal stability of target proteins (PLK1). They observed
that PLK1 was 1.4 times more stable against thermal denaturation with doses of a catalytic,
ATP-based inhibitor ranging from 0.03 µM to 3.0 µM. Dr. Wyatt’s lab performed a Western blot
assay to measure the phosphorylation of TCTP, which is a direct target of PLK1. They observed
that increasing the dose of 4-octyl S[pT]AI (a FLIP molecule) resulted in decreasing levels of
phosphorylated TCTP while the overall total of TCTP in the cell was unchanged. (Baxter et al.,
2020). These experiments confirmed that optimized FLIPs inhibit the PBD in a cellular context,
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which promotes further research on the development of PBD inhibitors and generation of FLIPs
with improved binding affinity to PLK1 PBD.
Objectives of Study
The main objective of this study was to determine the IC50values for a series of ABBA
and FLIP molecules with slight chemical alterations in order to determine an inhibitor that will
be highly selective for PLK1 PBD in cancer cells. The type of study that was performed is called
a structure-activity relationship (SAR) analysis because it involved observing changes in
biological activity due to altering the chemical structures of the inhibitor molecules. Each
molecule obtained from Dr. McInnes’ lab has a DDBS ID that categorizes it for continued
research.
The first set of molecules that were tested were FLIPs 6303, 6213, 6089, 6091, and 6068.
Molecule 6303 has 4 carbons on the alkyl tail (C4), 6213 has 6 carbons (C6), 6089 has 8 carbons
(C8), and 6091 has 9 carbons (C9). Computer modeling performed in Dr. McInnes’s lab showed
that PLK1 PBD has a hydrophobic binding region where the alkyl tail fits into the binding
pocket, so it was expected that increasing the hydrophobic alkyl tail on the FLIP would increase
its binding affinity for PLK1. FLIP 6208 is a non-phosphorus version of a FLIP. It was expected
to be inactive because the PLK1 PBD has a phosphothreonine binding site; the interaction
between the FLIP and PLK1 PBD is thought to be mediated by the phosphate group.
The next set of molecules that were tested were 6286 and 6287, which are ABBAs. Both
of these molecules contain phosphate groups that have replaced carboxyl groups. It was expected
that these molecules would have a higher binding affinity for PLK1 PBD than other ABBA
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molecules because the FLIPs contain a phosphate group and overall have much lower IC50values
than ABBAs.
Another molecule that was tested was 6320, which has a phosphoserine (P-Ser) amino
acid residue. Most of the FLIPs have phosphothreonine (P-Thr) residues to interact with the
P-Thr binding site on PLK1. This molecule was tested to determine if chemically changing the
amino acid residue on a FLIP affects its overall binding to the PLK1 PBD. Two ABBA
molecules that were tested were 6068 and 6069, which have chemical alterations on R5. 6068
has 2 carbons on R5 and 6069 has 3 carbons on R5. These molecules were tested to compare
their IC50values to those of other ABBA molecules and observe if increasing the number of
carbons on R5 increases their binding affinity to PLK1 PBD. Molecules 6125, 6274, and 6277
are ABBA molecules that were tested with PLK3 PBD to determine if they have a high
specificity to PLK1 based on their PLK1 PBD IC50 values. The PLK1 PBD IC50 values for these
three molecules were determined by Danda Chapagai in Dr. Wyatt’s lab prior to the completion
of this project.
In total, 26 molecules were tested for this project. Each molecule had slight chemical
modifications, and the IC50values were determined to guide the process of synthesizing a
molecule that has the greatest affinity and specificity to PLK1 PBD.
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Methodology
Fluorescence Polarization Assay
Multiwell Plate reader
To determine the IC50values for the ABBA and FLIP molecules, a Fluorescence
Polarization (FP) assay was used. This assay requires the use of a multiwell plate reader, which
emits polarized light at an excitation wavelength of 485 nm and an emission wavelength of 535
nm. The polarized light excites a fluorescent tracer that emits light which can be picked up by the
reader. When the fluorescent tracer peptide is not bound to a protein, it tumbles rapidly and
causes the emitted light to be depolarized. When the tracer binds to a high molecular weight
protein, the rotation is slowed, and the polarization signal read by the plate reader is high. The FP
assay can be used to examine the binding affinity of competitive inhibitor molecules to PLK1
PBD because when the tracer is bound to the PLK1 PBD active site, the polarization signal is
high. When the inhibitor binds to the PBD protein, there is much more freely floating tracer,
which causes a low polarization signal (Figure 3). The plate reader takes two fluorescence
measurements for each selected row of wells on the plate, perpendicular (s) and parallel (p). The
total fluorescence is calculated using Equation 1, and the fluorescence polarization values are
calculated by the plate reader using Equation 2 (Lea & Simeonov, 2011).

Equation 1: T otal F luorescence = s + 2p
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p−s

Equation 2: F P = p+s

Figure 3: The Fluorescence Polarization assay involves a fluorescent peptide, FITC, binding to a protein to
create a slow-tumbling complex. When an inhibitor molecule, shown in red, is introduced, it replaces the FITC in
the protein binding site, and the free-floating FITC peptide is recognized by the plate reader as a low polarization
signal.

FITC1 and PLK1 optimization
Before performing the FP assay, the optimal concentration of both fluorescent tracer
(FITC1) and protein (PLK1) were determined. The tracer needed to be optimized because if the
concentration used in the FP assay was too high, the plate reader would be unable to distinguish
between slight differences in signal. Using too low of a concentration would prevent the plate
reader from being able to pick up the signal. To optimize the tracer, a 1x buffer solution was
created using 2x buffer, 20nm DTT (Dithiothreitol), and nH2O. New 1x buffer was created for
each new experiment throughout this project. A serial dilution was performed to create solutions
of 1x buffer and FITC1 ranging from 0.1 nM to 300 nM. Each FITC1 concentration was
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multiplied by three for the purpose of performing the calculations because the solutions were
pipetted as triplicates (into three wells). Nine rows of 3 wells of the FITC1 and buffer solutions
were pipetted into a 384-well standard opaque plate. The plate was run through the plate reader,
and the optimal tracer concentration was determined to be 10 nM, which is 30 nM when using
triplicates.
The protein then needed to be optimized based on the concentration of tracer to be used
in the FP assay. Eleven solutions of PLK1 and 1x buffer were created ranging from 0.5 ng/well
to 350 ng/well. The 1x buffer was pipetted into three wells to be used as a control for the plate
reader. In the rows below the 1x buffer, 5 μL of tracer and 10 μL of PLK1 PBD buffer solution
was pipetted into each well. Each row contained a different concentration of PLK1 PBD. The
plate was read and analyzed by the plate reader, and an EC90value was calculated. The EC90
value is the protein concentration when 90% of the tracer is bound to the protein. It was
determined to be 159 ng/well.
FP Assay Protocol
Following the optimization of tracer and PLK1, the FP assay protocol was performed on
a series of molecules. One to two molecules were tested during each experiment. To begin the
assay, a new batch of 1X buffer solution was created and vortexed. The 1X buffer was used to
dilute the protein and inhibitor molecules, and served as a medium in which the protein was
stable. Then, the inhibitor molecule and 1X buffer solutions were created based on the specific
molecule being tested. Because the ABBA molecules have less affinity for PLK1 PBD than the
FLIPs, they were tested at higher concentrations. While FLIPs were tested within a concentration
range of 0.12-20 μM, the ABBAs were typically tested within a range of 5-200 μM. Table 1
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displays an example of the inhibitor and 1X buffer volume needed to create specific
concentrations of inhibitor following the performance of simple calculations. Most of the
molecules were tested using 7 different doses. The range of concentrations selected was based on
what the expected IC50value was for the molecule being tested based on preliminary data.
Results showing at least two doses above the IC50value and at least two doses below were
preferable for determining the most accurate value.

Final 1X
Concentration (μM)

3X Concentration
(μM)

Volume of Inhibitor
(μL)

Volume of 1X buffer
(μL)

Total (μL)

0.12

0.36

12 of 1.08 μM

24

36

0.36

1.08

12 of 3.24 μM

24

36

1.08

3.24

9.72 of 12 μM

26.28

36

4

12

14.4 of 30μM

21.6

36

10

30

20 of 60 μM

20

40

20

60

27 of 100 μM

18

45

100

300

1.8 of 10,000 μM
stock

58.2

60

Table 1: E
 xample of the table layout used in each experiment. The volume of inhibitor and 1X buffer used for each
dose depended on the final 3X concentration and the final volume needed.

Once the inhibitor solutions were pipetted into low protein-binding tubes and vortexed,
BSA buffer was created using 50 mM Tris HCL pH8, 10 mg/mL BSA, and nH2O. The BSA
buffer can be frozen and thawed up to five times, so it did not need to be made for every
experiment. Then, a 31.8 ng/well PLK1 PBD and buffer solution was made; the amount of
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PLK1PBD and 1x buffer used differed based on the amount needed for each experiment. Before
the FITC1 was removed from the aluminum foil wrapping, overhead lighting was turned off
because of its light sensitivity. FITC1 and BSA buffer were mixed to create a 30 nM solution.
Once all of the 1x buffer, inhibitor, tracer, and protein solutions were made, 15 μL of 1x
buffer was pipetted into each of 3 wells in the first row. Next, 10 μL of 1x buffer and 5 μL of
tracer were pipetted into each of the 3 wells in the second row. Then, 5 μL of 1x buffer, 5 μL of
tracer, and 5 μL of protein were pipetted into each of 3 wells in the third row. In the fourth row
and the rows below, 5 μL of tracer, 5 μL of protein, and 5 μL of inhibitor compound were
pipetted. Each row contained a different concentration of inhibitor. The plate was then
centrifuged at 500 rpm for 1 minute, placed on a shaker for 45 minutes, and centrifuged again.
The plate was then read by the plate reader.
Data Collection
The data was collected from the plate reader in the form of an Excel spreadsheet that
displayed the raw fluorescence and the fluorescence polarization values for each well in the
selected frame. This data was transferred to an Excel template used for calculating the total
fluorescence from the raw values. The template also calculated the logarithmic concentrations,
the average polarization values, the normalized average values, the percent of tracer bound to the
protein, and the standard deviations of the average values.
GraphPad’s Prism program is a graphing and analysis computer tool built for scientific
research. The log-concentration values and the percent bound values were inputted into this
program, and it performed a log-dose versus response analysis to create a sigmoidal curve that
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best fit the data. From this curve, the program calculated the IC50 value. The FP assay protocol
and data analysis were performed on each molecule.
Molecules Tested

Table 2.1: The chemical structures of the ABBA molecules tested.

Table 2.2: The chemical structures of the FLIP molecules tested.

Results

Table 3: Raw data for molecule 6303. The perpendicular (s) and parallel (p) raw fluorescence values were
determined by the plate reader. The total fluorescence values for each well were calculated in an Excel template
using Equation 1, and the average and standard deviation were calculated.

18

Table 4: Fluorescence polarization (FP) values for molecule 6303. The FP values for each well were determined by
the plate reader using Equation 2 . This Excel template was used to calculate the average FP values, normalized
average, percent of tracer bound to the protein, and the standard deviation.

PLK1 PBD Inhibition by 6303

Figure 4: The log-concentration versus percent of tracer bound to PLK1 PBD for molecule 6303 created by the
GraphPad program. The IC50 value was determined to be 6.345 μM.
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Figure 5: The log-concentration versus percent of tracer bound to PLK1 PBD for molecules 6213, 6089, 6091, and
6208 created by the GraphPad program. The IC50 values
were determined to be 3.123 μM, 1.881 μM, 0.8682 μM,

and undetermined, respectively. Molecule 6208 was inactive in the FP assay.
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Figure 6:  The log-concentration versus percent of tracer bound to PLK1 PBD for molecules 6286 and 6287. The
IC50 value
for molecule 6286 was determined to be 52.98 μM. The IC50 value
for molecule 6287 was determined to


be 74.06 μM. The data collected for molecule 6286 is preliminary data because only one dose is present below the
IC50 value.

Figure 7: The log-concentration versus percent of tracer bound to PLK1 PBD for molecule 6320. The IC50 value
was determined to be 9.649 μM.
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Figure 8: The log-concentration versus percent of tracer bound to PLK1 PBD for three trials of molecule 6068
(LW10, LW12, and LW13) and one trial of 6069. The IC50 values
for 6068 were determined to be 24.64 μM, 14.76

μM, and 15.60 μM for each trial respectively. The IC50 value for molecule 6069 was determined to be 9.649 μM,
which is preliminary data due to the lack of more than one dose below the IC50 value.
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Figure 9: The log-concentration versus percent of tracer bound to PLK3 PBD for molecules 6125, 6274, and 6277.
The IC50  values were determined to be 38.37 μM, 21.67 μM, and 28.61 μM, respectively.

ABBA PLK1 PBD

Table 5.1: A complete library of ABBA molecules tested with PLK1 PBD during this project and their IC50  values.
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FLIP PLK1 PBD

Table 5.2: A complete library of FLIP molecules tested with PLK1 PBD during this project and their average IC50
values.

ABBA PLK3 PBD and PLK1 PBD

Table 5.3: A complete library of ABBA molecules tested with PLK3 PBD during this project and their IC50  values.
The PLK1 PBD IC50  values for these molecules were used to calculate their selectivity index for PLK1.
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Discussion/Conclusions
Targeting PLK1 PBD for inhibition by a small molecule inhibitor has the potential to be
exploited as a cancer therapy due to the role of PLK1 in the overproliferation of cells. For a
cancer drug of this type to be successful and have limited off-target effects, it must possess a
high affinity for PLK1. FLIP molecules 6303, 6213, 6089, 6091, and 6208 were tested to
determine if the length of the alkyl tail increased their affinity for PLK1 PBD. A model of the
crystalline structure of the PBD showed that it contains a hydrophobic pocket in the binding
region next to the phosphothreonine binding site, and it was expected that adding carbons to the
alkyl tail of a FLIP molecule would cause it to better fit the PBD. Tables 3 and 4 as well as
Figures 4 and 5 show that the IC50value decreased with each FLIP modification to extend the
alkyl tail, meaning that its affinity for PLK1 PBD increased. Molecule 6208 was tested as a
negative control because it lacks a phosphate group. It was expected to be inactive because the
PBD on PLK1 has a phosphothreonine binding site, and its inactivity in the FP assay suggests
that the interaction between the FLIP and PLK1 PBD is mediated by the phosphate group. As
expected, 6208 was inactive in the FP assay. Molecule 6091, having 9 carbons on the R1
position had the lowest IC50value compared to the others in this group of molecules tested.
These results further confirm the hydrophobic structure of the PBD that was observed on its
modeled crystalline structure.
Molecules 6286 and 6287 are modified ABBA molecules with a phosphate group
replacing the carboxyl group on the R3 position. Phosphate groups possess similar geometry to
carboxyl groups, and they are both negatively charged. Molecule 6286 was found to have an
average IC50value of 52.98 (Figure 6), which is higher than the three other ABBA molecules

25

tested during this project (Table 5.1). This result is the opposite of what was expected because
FLIP molecules contain phosphate groups and have a much higher affinity to PLK1 PBD than
ABBA molecules. Phosphate groups are more electronegative and have a slightly larger size than
carboxyl groups which could have affected its position when binding to the histidine and lysine
residues of the PBD. This result has guided the development of other ABBAs to contain carboxyl
groups rather than phosphate groups, as it was determined that the phosphate group in position
R3 caused the inhibitor to have less affinity for PLK1 PBD. The IC50value for molecule 6287
was determined to be 74.06 μM, which is preliminary data. This is because, as seen in Figure 6,
only one dose below the IC50value was tested, which can be a source of error in the data. Further
tests will need to be performed with higher doses to confirm the average The IC50value for
molecule 6287.
The majority of molecules tested during this project contained a phosphothreonine
(P-Thr) residue which bound to the P-Thr binding site on PLK1 PBD. Molecule 6320 was
modified to contain a phosphoserine (P-Ser) residue. The IC50value was calculated to be 9.649
for this molecule which is higher than all of the other FLIPs that were tested (Figure 7). This
result suggests that the substrate binding site acts in concert with the hydrophobic pocket on the
PBD when binding its substrate. Altering the amino acid residue affects the interaction between
FLIP molecules and PBD. Molecules 6068 and 6069 are ABBA molecules with chemical
alterations on position R5. As shown in Figure 8, molecule 6068 was found to have an average
IC50value of 18.3, which was calculated from the performance of three FP assays. The IC50value
for molecule 6069 was found to be much greater at 72.06. Inserting an additional carbon onto R5
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decreased the molecule’s affinity to PLK1 PBD substantially, showing that this modification is
not beneficial in guiding the development of an anti-cancer drug.
ABBA molecules 6125, 6274, and 6277 were tested with PLK3 PBD to determine their
specificity to PLK1. PLK1 binds five times more strongly to FITC1 than PLK3 bids to FITC3, so
the PLK3 PBD IC50 values for these molecules were multiplied by five to determine their
selectivity indexes for PLK1 (Table 5.3). These three molecules have relatively low selectivity
indexes for PLK1, so using these structures to guide the development of a drug would be
problematic. Drugs with low specificity to PLK1 could cause a cell to proliferate out of control
because of the tumor-suppressing function of PLK3 in dividing cells.
Each molecule tested during this project provided data that guided the development of
new molecules. Chemical alterations were made to ABBA and FLIP molecules based on the
crystalline structure of the PLK1 PBD, and the FP assay results showed how each alteration
affected inhibitor-domain binding. The results also provided additional information about the
chemical structure of the PBD.
The molecules displayed in Tables 5.1, 5.2, and 5.3 that contain more than one
experiment number were tested more than once, and their IC50values were averaged to obtain the
most accurate value. Many FP assays that were performed resulted in unusable data, and those
molecules were retested because of concerning values noticed in the raw data. The total
fluorescence values for the wells containing only 1X buffer were expected to be between 5,000
and 7,000, as seen in Table 3, and some experiments resulted in values above 20,000. This high
value suggested that there could have been dust or some other material in the wells before the
buffer was pipetted into them, which could have affected the data for the other wells in the plate.
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Another set of values that were important to check before analyzing the data were the normalized
FP values, which should have a wide range as seen in Table 4 (26.8 mP to 165.3 mP). Some
experiments resulted in a window of only about 10 mP or less, which affected the percent bound
data, and every concentration of protein showed almost 100% bound. Other experiments needed
to be repeated because the highest concentration of inhibitor used resulted in a percent bound
value higher than 50%. This meant that the concentrations used in the following trial needed to
be higher so that it would result in at least two doses below the molecule’s IC50value. Reviewing
the raw data and repeating experiments in this project facilitated the calculation of the most
accurate IC50 values for the molecules that were tested.
Future directions for this research include making further modifications to the FLIP and
ABBA molecules to continue determining a chemical structure that has a high affinity and
specificity to PLK1 PBD. Adding an NH2 group to the molecule could neutralize its charge and
allow it to more effectively cross the lipid bilayer of the cell membrane, which would be
beneficial in the development of a drug that acts inside of the cell. Another potential
modification could be the addition of heteroatoms such as fluorine (F) to the chemical structure,
which act as electron-withdrawing groups. This could enhance the ionic interactions that occur in
the PBD and lower the IC50value of the modified molecule. The molecules tested with the FP
assay that have high affinity and specificity to PLK1 PBD could be tested with actual cell lines
to observe how well they cross the cell membrane and bind to PLK1 PBD. The inhibitor’s effect
on the cell could be observed by capturing images of the cells during mitosis. One of the desired
effects of a small-molecule inhibitor anti-cancer drug is to disrupt mitosis and induce apoptosis
of the cancer cell. Observing that the chromosomes split three ways instead of two during
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anaphase, or did not separate properly, would increase confidence that the structure of the
inhibitor molecule tested has potential to be developed into a successful anti-cancer drug.

29

References
Abdelfatah, S., Berg, A., Bockers, M., Efferth, T. (2019). A selective inhibitor of the Polo-box
domain of Polo-like kinase 1 identified by virtual screening. Journal of Advanced
Research, 16, 145-156.
Baxter, M., Chapagai, D., Craig, S., Hurtado, C., Varghese, J., Nurmemmedov, E., Wyatt, M. D.,
McInnes, C. (2020). Peptidomimetic Polo-Box targeted inhibitors that engage PLK1 in
tumor cells and are selective against the PLK3 tumor suppressor. Manuscript.
https://chemistry-europe.onlinelibrary.wiley.com/doi/abs/10.1002/cmdc.202000137
Elez, R., Piiper, A., Kronenberger, B., Kock, M., Brendel, M., Hermann, E., Pliquett, U.,
Neumann, E., Zeuzem, S. (2003). Tumor regression by combination antisense therapy
against PLK1 and Bcl-2. Oncogene, 9;22 (1), 69-80.
Elia, A. E., Rellos, P., Haire, L. F., Chao, J. W., Ivins, F. J., Hoepker, K., Mohammad, D.,
Cantley, L. C., Smerdon, S. J., Yaffe, M. B. (2003). The molecular basis for
phospho-dependent substrate targeting and regulation of Plks by the polo-box domain.
Cell 115, 83–95.
Hanahan, D., and Weinberg, R. (2011). Hallmarks of Cancer: The Next Generation. Cell, 144( 5),
646-674.
Lea, W., and Simeonov,. A. (2011). Fluorescence Polarization Assays in Small Molecule
Screening. Expert Opinion on Drug Discovery, 6(1), 17-32.
Liu, Z., Sun, Q., Wang, X. (2016). PLK1, A Potential Target for Cancer Therapy. Translational
oncology, 10(1), 22-32.
McInnes, C., and Wyatt, M.D. (2011). PLK1 as an oncology target: current status and future

30

potential, Drug Discovery Today, 16(13-14), 619-625.
McKenzie, L., King, S., Marcar, L., Nicol, S., Dias, S. S., Schumm, K., Robertson, P., Bourdon,
J., Perkins, N., Fuller-Pace, F., Meek, D. W. (2015). p53-dependent repression of
polo-like kinase-1 (PLK1). Cell Cycle, 9( 20), 4200-4212.
Strebhardt, K. and Ullrich, A. (2006). Targeting polo-like kinase 1 for cancer therapy.
Nature Reviews Cancer, 6, 321–330.
Strebhardt, K. (2010). Multifaceted polo-like kinases: drug targets and antitargets for cancer
therapy. Nature Reviews Drug Discovery, 9( 8), 643-660.

31

